Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates- an Updated Report from the Asia-Pacific Multinational Retrospective Registry
第一作者机构:[1]Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
推荐引用方式(GB/T 7714):
Cho Hyungwoo,Yoon Dok Hyun,Chan Jason Yongsheng,et al.Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates- an Updated Report from the Asia-Pacific Multinational Retrospective Registry[J].BLOOD.2024,144:doi:10.1182/blood-2024-202823.
APA:
Cho, Hyungwoo,Yoon, Dok Hyun,Chan, Jason Yongsheng,Kim, Dajung,Huang, Haiwen...&Kim, Won Seog.(2024).Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates- an Updated Report from the Asia-Pacific Multinational Retrospective Registry.BLOOD,144,
MLA:
Cho, Hyungwoo,et al."Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates- an Updated Report from the Asia-Pacific Multinational Retrospective Registry".BLOOD 144.(2024)